Table 1.
Case of aortic involvement in granulomatosis with polyangiitis.
| Case | Age/gender (years) | Affected site | Antibodies | Duration of complaint | Treatment | Rupture | Outcome |
|---|---|---|---|---|---|---|---|
| 1 [1] | 38/M | TAA | Anti-neutrophil cytoplasmic antibodies × 128 | NS | Surgery (J-graft) + PSL 15 mg/day | Yes | Good |
| 2 [13] | 51/M | Distal part of aorta (3.8 cm) | Anti-proteinase-3 antibodies > 530 kU/L | 2 months | Steroid pulse + PSL 1 mg/kg + CY 2 mg/kg/day | No | Good |
| 3 [14] | 45/M | Aorta, extending to the right iliac artery | ANCA + NS | 5 days | Right ureterolysis + immunosuppressive therapy | No | Good |
| 4 [15] | 33/M | AAA | Antiproteinase-3 (>1/10) | 3 weeks | IJV graft + PSL + CY | No | Good |
| 5 [16] | 42/M | AAA | Antiproteinase-3 157 AU/l | 1 month | Aortoiliac graft and high-dose PSL + CY 2 mg/kg/day | No | Good |
| 6 [17] | 63/M | AAA (5.4 cm) | p-ANCA 1/80 and MPO 28 U/l | 2 months | Surgery + PSL 1 mg/kg + CY 2 mg/kg | No | Good |
| 7 [18] | 50/F | TAA | p-ANCA (1 : 320) antimyeloperoxidase 440 U/ml | 2 months | PSL + CY | Yes | Death |
| 8 [19] | 43/M | Infrarenal aorta (3.1 × 3.5 cm) | NS | 1 week | PSL + surgery | No | Good |
| 9 [20] | 29/M | Branches of hepatic and renal arteries | Anti-PR3 ANCA 15 IU/mL | NS | Coil embolization + steroid pulse + PSL 60 mg + MMF 2.5 g | No | Good |
| 10 [21] | 34/M | Anterior choroidal artery | PR3 ANCA 457 EU | 1 year | Clipping + steroid pulse + PSL 40 mg + CY | Yes | Good |
| 11 [22] | 67/M | Superior pancreaticoduodenal artery | C-ANCA 1 : 512 PR3 ANCA 88 IU/L | 11 months | IVCY (0.7 g/m2) every 3 weeks + steroid pulse + PSL 1 mg/kg/day | Yes | Death |
| 12 [23] | 58/F | Subclavian aneurysm | P-ANCA 68 units | 2 months | PSL 1 mg/kg + CY 2 mg/kg + stent graft | No | Good |
| 13 [24] | 56/M | Left gastric artery | C-ANCA positive | 1 month | None | Yes | Death |
| 14 [25] | 55/M | Hepatic artery | C-ANCA 1 : 80 | 3 weeks | mPSL + CY | Yes | Death |
| 15 [26] | 24/M | Bilateral renal artery | NS | 6 weeks | PSL 30 mg + CY 150 mg/day | Yes | Good |
| 16 [27] | 59/M | Aorta | C-ANCA 158 SLI units | 9 months | Coronary artery bypass + steroid pulse + PSL + CY 3 mg/kg + plasmapheresis | No | Good |
| 17 [28] | 35/M | Hepatic, renal, splanchnic | C-ANCA positive | 6 weeks | Steroid pulse + PSL + IVCY 750 mg | Yes | Good |
| 18 [29] | 30/M | Renal artery | NS | 1 month | PSL 1 mg/kg/day and CY 2 mg/kg/day | No | Good |
| 19 [30] | 53/F | Renal artery | NS | 20 days | PSL 1 mg/kg/day + CY 2 mg/kg/day + hemodialysis | No | Good |
| 20 [30] | 79/M | TAA | PR3-ANCA 1180 EU | 8 months | Steroid pulse PSL 60 mg + IVCY 300 mg | Yes | Death |
| Present case | 58/M | AAA | PR3 ANCA 187 IU/ml | 2 weeks | Steroid pulse + PSL 55 mg + IVCY 500 mg | No | Good |
TAA: thoracic aortic aneurysm; AAA: abdominal aortic aneurysm; F: female; M: male; NS: not stated; PSL: prednisolone; CY: cyclophosphamide; mPSL: methylprednisolone; MMF: mycophenolate mofetil; IVCY: intravenous cyclophosphamide; IJV: internal jugular vein.